While highly effective modulator therapies (HEMTs) have significantly improved CF lung disease management, non-pulmonary co-morbidities remain a major challenge, impacting quality of life and long-term survival. These include CF-related diabetes (CFRD), CF-related bone disease (CFBD), CF-related liver disease (CFLD), and CF-related mental health and gastrointestinal issues. 

Given the complexity of CF, interdisciplinary, phenotype-based precision medicine is crucial for improving long-term management of pulmonary and non-pulmonary disease. To support this, the CF Discovery Core provides:

1. Access to the CF-BR – A comprehensive collection of biological samples from PwCF (including healthy and lung disease controls), gathered longitudinally across various health states.
2. Access to clinical data through the Georgia Cystic Fibrosis Data Warehouse – Linking biospecimens with extensive, de-identified patient data to support integrated research.
3. Expert scientific consultation – A Research Oversight Committee (ROC) of biostatisticians, clinicians, and researchers ensures rigor and feasibility in study design.

The CF Discovery Core is made possible by the generosity of patient volunteers from the Children’s+Emory CF Care Center. With ~700 PwCF in our adult and pediatric programs, nearly 70% participate, contributing invaluable samples and clinical data. This unique resource bridges basic research and real-world clinical outcomes, driving meaningful advancements in CF care.

The CF Discovery Core is funded by the Marcus Foundation Professorship in Pulmonology for Dr. Stecenko, Children’s Healthcare of Atlanta, NIH P30 DK125013 and NIH U24 HL17672.